



## Drug Delivery in Ophthalmology

Guest Editor:

### Prof. Dr. Yvan Arsenijevic

Unit of Retinal Degeneration and Regeneration, Department of Ophthalmology, University of Lausanne, Hôpital Ophtalmique Jules-Gonin, Fondation Asile des aveugles, 1004 Lausanne, Switzerland

Deadline for manuscript submissions:

**closed (10 November 2022)**

### Message from the Guest Editor

Dear Colleagues,

The eye is an interesting organ for drug delivery development owing to its accessibility and monitoring feasibility to record physiological activity versus morphological features. The progress in our comprehension of disease mechanisms has made it possible to identify multiple targets to develop new treatments for inherited retinal dystrophies and glaucoma. However, small molecules often have a very short half-life in the eye, rendering repetitive treatments problematic. Concerning genetic diseases, gene transfer has brought great success with the proof-of-concept that a gene augmentation strategy can restore some visual functions over the course of months or even years. Many clinical trials are ongoing, but few data are available about the patients or from a methodological point of view.

This Special Issue aims to present different reviews on the successes, hurdles, and potential solutions with drug delivery into the eye using small molecules such as nanodrugs, nonviral and viral drug delivery, as well as antisense oligonucleotides, and to help each researcher choose the adequate tool for the disease which they aim to target.

Prof. Dr. Yvan Arsenijevic





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Ernest Mario School of  
Pharmacy, Rutgers, The State  
University of New Jersey, William  
Levine Hall, Room 225C, 160  
Frelinghuysen Road, Piscataway,  
NJ 08854-8020, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

*Pharmaceutics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma